Final extension for AsiaPharm takeover set for May 22
MBK Partners stands firm on its takeover offer which, as of April 30, had been accepted by 77.19% of AsiaPharmÆs shareholders. Templeton remains opposed to the deal.
Private equity firm MBK PartnersÆ takeover offer for Singapore-listed drug company AsiaPharm Group has been extended to May 22, according to ABN Amro Bank, which is advising MBK on the deal.
MBK Partners has stood firm on the S$0.725 $0.53 per share offer price of Lu Ye Pharmaceutical Investment, which it controls, in a deal valued at S$357.4 million $262.6 million. The offer had been accepted by 77.19% of AsiaPharmÆs shareholders as of April 30. This includes...
To continue reading, please login or register for free